T. Rowe Price Investment Management, Inc. Immatics N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immatics N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 19,383,169 shares of IMTX stock, worth $198 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
19,383,169
Previous 18,328,455
5.75%
Holding current value
$198 Million
Previous $98.6 Million
67.48%
% of portfolio
0.1%
Previous 0.06%
Shares
10 transactions
Others Institutions Holding IMTX
# of Institutions
68Shares Held
93.1MCall Options Held
53.8KPut Options Held
0-
Baker Bros. Advisors LP New York, NY12.1MShares$123 Million0.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$123 Million3.08% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$95.7 Million0.18% of portfolio
-
Rtw Investments, LP New York, NY8.82MShares$89.9 Million1.0% of portfolio
-
Vestal Point Capital, LP New York, NY6.35MShares$64.8 Million2.44% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $778M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...